Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Contineum Therapeutics, Inc. - Common stock (NQ:CTNM)

5.270 +0.090 (+1.74%)
Streaming Delayed Price Updated: 2:38 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 78,476
Open 5.240
Bid (Size) 5.270 (1)
Ask (Size) 5.340 (6)
Prev. Close 5.180
Today's Range 5.150 - 5.500
52wk Range 3.350 - 21.66
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
From Contineum Therapeutics, Inc.
Via Business Wire

Performance

YTD
-63.6%
-63.6%
1 Month
+27.9%
+27.9%
3 Month
+7.6%
+7.6%
6 Month
-53.3%
-53.3%
1 Year
-75.4%
-75.4%

More News

Read More
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
New Oriental Education, Walgreens And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
From Contineum Therapeutics, Inc.
Via Business Wire
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
From Contineum Therapeutics, Inc.
Via Business Wire
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics to Attend Upcoming Investor Conferences
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
From Contineum Therapeutics, Inc.
Via Business Wire
CTNM Stock Earnings: Contineum Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis
From Contineum Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Contineum Therapeutics, Inc. - Common stock publicly traded?
Yes, Contineum Therapeutics, Inc. - Common stock is publicly traded.
What exchange does Contineum Therapeutics, Inc. - Common stock trade on?
Contineum Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Contineum Therapeutics, Inc. - Common stock?
The ticker symbol for Contineum Therapeutics, Inc. - Common stock is CTNM on the Nasdaq Stock Market
What is the current price of Contineum Therapeutics, Inc. - Common stock?
The current price of Contineum Therapeutics, Inc. - Common stock is 5.270
When was Contineum Therapeutics, Inc. - Common stock last traded?
The last trade of Contineum Therapeutics, Inc. - Common stock was at 07/23/25 02:38 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.